Theravance Biopharma Reports Positive New Data from Multiple Studies of VIBATIV® (telavancin) at 2018 ECCMID™ Conference

Data from TOUR™ Observational Patient Registry Demonstrate Clinical Response Rates with VIBATIV® (telavancin) Treatment Range from 76.5 – 78.8% for Obese and Elderly Patient Subgroups Additional Study Results Demonstrate VIBATIV to Have 8- to 32-Fold Greater in vitro Potency than Competitor

READ FULL TEXT

Leave a Reply

Your email address will not be published.